Literature DB >> 31492590

Atrial Myxoma Presenting as Acute Bilateral Limb Ischemia.

Roshan Mathew1, Naman Agrawal1, Praveen Aggarwal1, Nayer Jamshed1.   

Abstract

BACKGROUND: Cardiac myxoma is the most common primary benign tumor of the heart and it has diverse clinical presentations. It is known to embolize into systemic circulation. However, presentation with complete occlusion of the aorta is uncommon. CASE REPORT: We report an 18-year-old female who presented to the emergency department with features of acute bilateral limb ischemia. Arterial Doppler ultrasonography showed infrarenal aortic occlusion. A bedside cardiac ultrasound was done in the emergency department which clinched the diagnosis of atrial myxoma. Complete surgical excision of the tumor and subsequent histopathologic examination confirmed the diagnosis of atrial myxoma. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: This report puts emphasis on the fact that atrial myxoma, though rare, may be considered as a source of embolism in patients presenting with acute limb ischemia. The importance of bedside ultrasonography for early diagnosis in such presentations is also highlighted.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  POCUS; acute limb ischemia; myxoma

Mesh:

Year:  2019        PMID: 31492590     DOI: 10.1016/j.jemermed.2019.06.006

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  2 in total

1.  Point-of-care ultrasound to complete physical exam and to reach the diagnosis in a young man with syncope.

Authors:  Fatemeh Rasooli; Mehrnoosh Aligholi Zahraie; Maryam Bahreini
Journal:  Ultrasound J       Date:  2020-05-25

2.  Characterizations of Ischemic Stroke Complications in Cardiac Myxoma Patients at a Single Institution in Eastern China.

Authors:  Yanlei Zhang; Zusen Ye; Yun Fu; Zheng Zhang; Qiang Ye; Feichi Chen; Jianhua Cheng
Journal:  Neuropsychiatr Dis Treat       Date:  2021-01-07       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.